Xijing Hospital: Stroke trials

The registry lists 19 Stroke studies with Xijing Hospital as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 2 5Phase 3 3Phase 4 2No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Intermittent Enteral Feeding in Severe StrokeNot yet recruitingNCT07353658Not applicable
• Assessment and Management of Multiple Drug Use in Elderly Chronic Disease PatientsRecruitingNCT07180368
• Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)Active, not recruitingNCT05512910Phase 4
• Prevention and Treatment of Reperfusion Injury After Mechanical Thrombectomy in Acute Ischemic StrokeStatus unknownNCT05282290Not applicable
• Predictive Study of Serum Endocan for Hemorrhagic Transformation After Reperfusion Therapies in Acute Ischemic StrokeStatus unknownNCT05228080
• Management of TA in VaS-Patients and HTStatus unknownNCT04726007
• Low-dose Aspirin Therapy in Patients With Ischemic Stroke and MicrobleedsStatus unknownNCT04504864Phase 4
• Optimizing Early Enteral Nutrition in Severe StrokeTerminatedNCT02982668Not applicable
• Controlling Hypertension After Severe Cerebrovascular EventCompletedNCT02982655Not applicable
• Edoxaban for TIA and Acute Minor StrokeStatus unknownNCT02221102Phase 2/3
• The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation.Status unknownNCT02181374
• Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial FibrillationCompletedNCT02181361
• Acute Stroke Advancing Program Using TelemedicineStatus unknownNCT02088346
• Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular EventsStatus unknownNCT01923818Phase 2/3
• Mildronate for Acute Ischemic StrokeCompletedNCT01831011Phase 2
• Efficacy and Safety of Mildronate for Acute Ischemic StrokeStatus unknownNCT01800357Phase 2
• China Stroke Secondary Prevention TrialWithdrawnNCT01317849Not applicable
• Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic StrokeCompletedNCT00815763Phase 3
• Ginsenoside-Rd for Acute Ischemic StrokeCompletedNCT00591084Phase 2